Stoke Therapeutics Stock Performance

STOK Stock  USD 32.40  1.92  6.30%   
On a scale of 0 to 100, Stoke Therapeutics holds a performance score of 9. The entity has a beta of 0.37, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Stoke Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Stoke Therapeutics is expected to be smaller as well. Please check Stoke Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Stoke Therapeutics' existing price patterns will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Stoke Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating basic indicators, Stoke Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(1.27)
Five Day Return
(6.22)
Year To Date Return
3.53
Ten Year Return
25.11
All Time Return
25.11
Last Split Factor
1:9
Last Split Date
2019-06-06
1
Disposition of 25000 shares by Kaye Edward M. Md of Stoke Therapeutics at 0.6 subject to Rule 16b-3
11/21/2025
2
Disposition of 40472 shares by Adrian Krainer of Stoke Therapeutics at 29.7173 subject to Rule 16b-3
11/24/2025
3
Disposition of 868 shares by Allan Jonathan of Stoke Therapeutics at 30.1419 subject to Rule 16b-3
12/02/2025
4
Disposition of 1211 shares by Levin Arthur A of Stoke Therapeutics subject to Rule 16b-3
12/31/2025
5
Stoke Therapeutics, Inc. Stock Analysis Strong Buy Ratings Amid Impressive Revenue Growth and Promising Pipeline - DirectorsTalk Interviews
01/09/2026
6
A Look At Stoke Therapeutics Valuation After Accelerated Phase 3 Timeline For Dravet Therapy
01/13/2026
7
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
01/16/2026
8
Stoke Therapeutics, Inc. STOK is Skorpios Trusts Largest Position - MarketBeat
01/21/2026
9
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
01/26/2026
10
A Look At Stoke Therapeutics Valuation As New Waltham Headquarters Signals Growth Plans
01/30/2026
11
Disposition of 762 shares by Ticho Barry of Stoke Therapeutics at 30.1419 subject to Rule 16b-3
02/03/2026
Begin Period Cash Flow192 M
Total Cashflows From Investing Activities-107.5 M

Stoke Therapeutics Relative Risk vs. Return Landscape

If you would invest  2,513  in Stoke Therapeutics on November 12, 2025 and sell it today you would earn a total of  727.00  from holding Stoke Therapeutics or generate 28.93% return on investment over 90 days. Stoke Therapeutics is currently generating 0.5082% in daily expected returns and assumes 4.1518% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Stoke, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Stoke Therapeutics is expected to generate 5.13 times more return on investment than the market. However, the company is 5.13 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of risk.

Stoke Therapeutics Target Price Odds to finish over Current Price

The tendency of Stoke Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 32.40 90 days 32.40 
about 22.49
Based on a normal probability distribution, the odds of Stoke Therapeutics to move above the current price in 90 days from now is about 22.49 (This Stoke Therapeutics probability density function shows the probability of Stoke Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Stoke Therapeutics has a beta of 0.37. This usually implies as returns on the market go up, Stoke Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Stoke Therapeutics will be expected to be much smaller as well. Additionally Stoke Therapeutics has an alpha of 0.3823, implying that it can generate a 0.38 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Stoke Therapeutics Price Density   
       Price  

Predictive Modules for Stoke Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Stoke Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
28.7332.8536.97
Details
Intrinsic
Valuation
LowRealHigh
30.0134.1338.25
Details
10 Analysts
Consensus
LowTargetHigh
38.1241.8946.50
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.88-0.78-0.7
Details

Stoke Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Stoke Therapeutics is not an exception. The market had few large corrections towards the Stoke Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Stoke Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Stoke Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.38
β
Beta against Dow Jones0.37
σ
Overall volatility
2.99
Ir
Information ratio 0.07

Stoke Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Stoke Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Stoke Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Stoke Therapeutics appears to be risky and price may revert if volatility continues
Stoke Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 36.55 M. Net Loss for the year was (88.98 M) with profit before overhead, payroll, taxes, and interest of 205.63 M.
Stoke Therapeutics currently holds about 275.63 M in cash with (86.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99.
Stoke Therapeutics has a poor financial position based on the latest SEC disclosures
Over 96.0% of the company shares are owned by institutional investors
Latest headline from simplywall.st: Assessing Upstream Bio Valuation As VALINAT Phase 2 Readout And Verekitug Interest Drive Momentum

Stoke Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Stoke Stock often depends not only on the future outlook of the current and potential Stoke Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Stoke Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding54 M
Cash And Short Term Investments216.9 M

Stoke Therapeutics Fundamentals Growth

Stoke Stock prices reflect investors' perceptions of the future prospects and financial health of Stoke Therapeutics, and Stoke Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stoke Stock performance.

About Stoke Therapeutics Performance

By examining Stoke Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Stoke Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stoke Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.29)(0.31)
Return On Capital Employed(0.50)(0.48)
Return On Assets(0.29)(0.31)
Return On Equity(0.45)(0.42)

Things to note about Stoke Therapeutics performance evaluation

Checking the ongoing alerts about Stoke Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Stoke Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Stoke Therapeutics appears to be risky and price may revert if volatility continues
Stoke Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 36.55 M. Net Loss for the year was (88.98 M) with profit before overhead, payroll, taxes, and interest of 205.63 M.
Stoke Therapeutics currently holds about 275.63 M in cash with (86.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.99.
Stoke Therapeutics has a poor financial position based on the latest SEC disclosures
Over 96.0% of the company shares are owned by institutional investors
Latest headline from simplywall.st: Assessing Upstream Bio Valuation As VALINAT Phase 2 Readout And Verekitug Interest Drive Momentum
Evaluating Stoke Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Stoke Therapeutics' stock performance include:
  • Analyzing Stoke Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stoke Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Stoke Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Stoke Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stoke Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Stoke Therapeutics' stock. These opinions can provide insight into Stoke Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Stoke Therapeutics' stock performance is not an exact science, and many factors can impact Stoke Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
0.68
Revenue Per Share
3.547
Quarterly Revenue Growth
1.172
Return On Assets
0.052
Return On Equity
0.1502
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.